Orgenesis Announces Planned Study to Confirm Suitability of Liver Cells as a Source for Personalized Cell Replacement Therapy for ...
GERMANTOWN, Md., April 30, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced it has received Institutional Review Board (IRB) approval to collect liver …